Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2019-06-28 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于为控股子公司提供担保实施情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Shenzhen Haiwang Bioengineering Co., Ltd. regarding the provision of guarantees for its controlling subsidiaries. It includes specifics about guarantee amounts, counterparties (banks and financial institutions), contract terms, and cumulative guarantee balances. The document is an official announcement about the company's financing-related activities, specifically guarantees provided to support subsidiaries' credit facilities. It does not contain financial statements, audit opinions, or management discussions of financial results. It is not a report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript or AGM material. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company. The document length is substantial and contains detailed information, not just a brief notice or report publication announcement. Therefore, the classification is CAP with high confidence.
2019-06-28 Chinese
2017年面向合格投资者公开发行公司债券（第一期）受托管理事务报告（2018年度）
Audit Report / Information Classification · 95% confidence The document is titled as a "2017年面向合格投资者公开发行公司债券（第一期）受托管理事务报告（2018年度）" which translates to "2017 Qualified Investors Public Issuance of Corporate Bonds (First Issue) Trustee Management Affairs Report (2018 Annual)". It is a detailed report prepared by the trustee (Haitong Securities) regarding the management and oversight of a corporate bond issuance by Shenzhen Neptunus Bioengineering Co., Ltd. The content includes bond issuance details, issuer's 2018 operating and financial status, use of raised funds, debt repayment measures, interest payment status, bondholder meeting information, credit rating updates, and trustee duties. The document is not a general annual report of the company, nor is it an earnings release or a regulatory filing. It is a specialized report related to the trustee management of a corporate bond issuance for a specific year. This type of document fits best under the category of "Audit Report / Information (AR)" as it is a standalone report related to the bond issuance, its management, and financial oversight, excluding full annual reports or earnings releases. The document length (9159 characters) and detailed financial data support it being a full report rather than a brief announcement or certification. Therefore, the classification is AR with high confidence. FY 2018
2019-06-28 Chinese
主体及相关债项2019年度跟踪评级报告
Regulatory Filings
2019-06-26 Chinese
本次非公开发行股票摊薄即期回报对公司主要财务指标的影响及填补回报采取的措施和相关主体承诺的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding the impact of a non-public stock issuance on the company's key financial indicators and the measures taken to compensate for the dilution of immediate returns. It includes detailed analysis of financial metrics, assumptions, risk warnings, and commitments by the company's board and controlling shareholders to uphold these measures. The document references regulatory requirements from the China Securities Regulatory Commission and discusses the issuance of up to 552 million shares raising up to 2.5 billion RMB. The content focuses on the capital raising event, its financial impact, and related commitments rather than presenting a full financial report or earnings release. It is not a full annual or interim report, nor a simple announcement of a report. The document is a detailed update on the company's capital/financing activities and related shareholder commitments. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2019-06-25 Chinese
关于“17海王01”投资者回售结果的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the results of investor put-back (回售) for a specific bond "17海王01" issued by Shenzhen Haier Bioengineering Co., Ltd. It details the number of bonds put back, the amount, and the payment process to investors. There is no financial statement, management discussion, or detailed report content. The document is short (956 characters) and serves as an official notice of the outcome of a bond investor action. This fits the category of Capital/Financing Update (CAP), as it relates to bond financing and investor redemption results.
2019-06-25 Chinese
关于担保延续构成对外担保的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Shenzhen Haiwang Bioengineering Co., Ltd. regarding the continuation of guarantees provided to Sichuan Jinren Pharmaceutical Group Co., Ltd. It details the background, reasons, and terms of the guarantee extension, including board and supervisory opinions, financial figures related to guarantees, and related agreements. The document is an announcement about a specific financing-related matter (guarantee continuation) and does not contain comprehensive financial statements or quarterly/yearly financial results. It is not an annual report, interim report, earnings release, or audit report. It is also not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it concerns updates on company financing activities and guarantees. The document length is 4230 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2019-06-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.